Plumbagin suppresses non-small cell lung cancer progression through downregulating ARF1 and by elevating CD8+ T cells

Ze-Bo Jiang,Cong Xu,Wenjun Wang,Yi-Zhong Zhang,Ju-Min Huang,Ya-Jia Xie,Qian-Qian Wang,Xing-Xing Fan,Xiao-Jun Yao,Chun Xie,Xuan-Run Wang,Pei-Yu Yan,Yu-Po Ma,Qi-Biao Wu,Elaine Lai-Han Leung
DOI: https://doi.org/10.1016/j.phrs.2021.105656
IF: 10.334
2021-07-01
Pharmacological Research
Abstract:<p>Non-small cell lung cancer (NSCLC) is one of the most frequently diagnosed cancers and the leading causes of cancer death worldwide. Therefore, new therapeutic agents are urgently needed to improve patient outcomes. Plumbagin (PLB), a natural sesquiterpene present in many Chinese herbal medicines, has been reported for its anti-cancer activity in various cancer cells. In this study, the effects and underlying mechanisms of PLB on the tumorigenesis of NSCLC were investigated. PLB dose-dependently inhibited the growth of NSCLC cell lines. PLB promoted ROS production, activated the endoplasmic reticulum (ER) stress pathway, and induced cell apoptosis, accompanied by the decreased expression level of ADP-ribosylation factor 1 (ARF1) in NSCLC cancer cells, and those effects of PLB could be reversed by the pretreatment with N-acetyl-L-cysteine (NAC). More importantly, the calcium chelator (BM) significantly reversed PLB-induced cell apoptosis. Furthermore, PLB significantly inhibited the growth of both H1975 <em>xenograft</em> and LLC1 tumors and exhibited antitumor activity by enhancing the number and the effector function of CD8<sup>+</sup> T cells in KRASLA2 mice model and the LLC1 <em>xenograft</em>. Our findings suggest that PLB exerts potent antitumor activity against NSCLC <em>in vitro</em> and <em>in vivo</em> through ARF1 downregulation and induction of antitumor immune response, indicating that PLB is a new novel therapeutic candidate for the treatment of patients with NSCLC.</p>
pharmacology & pharmacy
What problem does this paper attempt to address?
The problem that this paper attempts to solve is the treatment of non - small - cell lung cancer (NSCLC). NSCLC is one of the most common cancers in the world and also one of the leading causes of cancer - related deaths. Therefore, there is an urgent need for new therapeutic agents to improve the prognosis of patients. This article studied the effect of plumbagin (PLB) on the progression of non - small - cell lung cancer and its underlying mechanisms. Specifically, the researchers explored the role of plumbagin in inhibiting the progression of non - small - cell lung cancer by down - regulating ADP - ribosylation factor 1 (ARF1) and increasing the number of CD8+T cells. The research results show that plumbagin exhibits significant anti - tumor activity both in vitro and in vivo, which provides a new candidate drug for the treatment of non - small - cell lung cancer.